Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Sep 29;4(4).
doi: 10.3402/jchimp.v4.24927. eCollection 2014.

Efficacy of NSAIDs for the prevention of acute mountain sickness: a systematic review and meta-analysis

Anil Pandit  1 , Paras Karmacharya  2 , Ranjan Pathak  2 , Smith Giri  3 , Madan R Aryal  2
Affiliations
Review

Efficacy of NSAIDs for the prevention of acute mountain sickness: a systematic review and meta-analysis

Anil Pandit et al. J Community Hosp Intern Med Perspect. .

Abstract

Background: Acute mountain sickness (AMS) can occur in anyone going to a high altitude. Non-steroidal anti-inflammatory drugs (NSAIDs) have been studied for the prevention of AMS with mixed results. In this systematic review, we analyze all existing data on the use of NSAIDs to prevent AMS using the Lake Louise Scoring System (LLSS) in different randomized clinical trials (RCTs).

Methods: Electronic literature searches for relevant studies were identified through MEDLINE, EMBASE, SCOPUS, and Cochrane library up to June 2013. RCTs involving NSAIDs compared to placebo in patients undergoing ascent to a height of at least 3,800 m were included. Odds ratios (OR) were calculated and combined using fixed-effect model meta-analysis if I (2)=0%. Differences between groups were calculated using the inverse variance of the standard mean differences. Between-study heterogeneity was assessed using the I (2) statistics.

Results: In three clinical trials involving 349 patients, AMS using LLSS occurred in 26.92% of patients on NSAIDs and 43.71% on placebo (OR 0.43; CI [confidence interval] 0.27-0.69, I (2)=0%, p=0.0005), NNT=6. Minor outcome of end point Spo2 was not significant in the two groups (IV=0.74; 95% CI -0.20-1.69, I (2)=81%, p=0.12). Similarly, a change in Spo2 from baseline was also not significant in the two groups (IV=0.05; 95% CI -0.28-0.37, I (2)=44%, p=0.78).

Conclusion: NSAIDs might be a safe and effective alternative for the prevention of AMS. However, further larger population studies and studies comparing NSAIDs to acetazolamide and dexamethasone in the future may provide further data to its relative efficacy.

Keywords: acute mountain sickness; altitude sickness; anti-inflammatory agents; headache; ibuprofen; non-steroidal.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
PRISMA flow diagram showing the screening and inclusion of the studies.
Fig. 2
Fig. 2
Meta-analysis of AMS incidence using the LLSS. Comparator: NSAIDs versus placebo.
See this image and copyright information in PMC

References

    1. Lipman GS, Kanaan NC, Holck PS, Constance BB, Gertsch JH. PAINS Group. Ibuprofen prevents altitude illness: A randomized controlled trial for prevention of altitude illness with nonsteroidal anti-inflammatories. Ann Emerg Med. 2012;59(6):484–90. - PubMed
    1. Eide RP, 3rd, Asplund CA. Altitude illness: Update on prevention and treatment. Curr Sports Med Rep. 2012;11(3):124–30. - PubMed
    1. Kayser B, Dumont L, Lysakowski C, Combescure C, Haller G, Tramèr MR. Reappraisal of acetazolamide for the prevention of acute mountain sickness: A systematic review and meta-analysis. High Alt Med Biol. 2012;13(2):82–92. - PubMed
    1. Sutton J, Coates G, Houston C. Seventh International Hypoxia Symposium. Lake Louise . Canada: Pergamon Press; 1991. The Lake Louise consensus on the definition of quantification of altitude illness; pp. 327–30.
    1. Imray C, Booth A, Wright A, Bradwell A. Acute altitude illnesses. BMJ. 2011;343:d4943. - PubMed

LinkOut - more resources